Essence pharmaceuticals terminates the development of two human monoclonal antibody products
-
Last Update: 2020-02-20
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
In the evening of February 19th, the essence pharmaceutical announced that it signed the cooperation and authorization agreement with Kadmon Corporation and LLC in October 29, 2015 to cooperate in the development of VEGFR-2 monoclonal antibody and PDL-1 monoclonal antibody product But up to now, the essence of pharmaceuticals said that the two products are still in the pre clinical research and development stage, and the research results and progress do not meet the expectations Considering the actual situation of market competition, it is expected that the benefits of the project are not obvious and the project faces great risks After consultation with kadmon company of the United States, it is decided to terminate the R & D work of the project New drug R & D is a high investment and high-risk project, and the R & D risk is inevitable The company is adjusting the R & D project structure, focusing more on the R & D of proprietary Chinese medicine and classic chemicals, and the secondary development of existing varieties, so as to improve the company's core competitiveness Adorable adorable
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![benzyl N-{2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl}carbamate](https://file.echemi.com/fileManage/upload/goodpicture/20210823/m20210823171124543.jpg)
